The Pharmacy and Poisons Board (PPB) on Wednesday, September 20, ordered all Kenyans to return Tamedol oral solution (Paracetamol oral solution, 120mg/5ml, 60 mls) manufactured by Biopharma LTD, Kenya.
In a statement, the board that the drug had failed to meet the prescribed market authorization requirements.
The decision to recall the drug followed a series of public complaints which prompted the board to test the specific drug manufactured by Biopharma LTD, Kenya.
Following the findings, the Pharmacy and Poisons Board directed all pharmaceutical outlets, healthcare facilities, healthcare professionals, and members of the public to take immediate action including quarantining the product.
Healthcare facilities are instructed to return the products to their respective suppliers, the board stated.
“Members of public are urged to return the product to their nearest healthcare facility, while healthcare facilities are instructed to return the products to their respective suppliers,” the board’s statement read.
“We encourage the public to remain vigilant at all times and promptly report any suspected cases of sub-standard medicines or adverse drug reactions to the nearest healthcare,” it added.
The board however dispelled fears indicating that it had instituted measures to guarantee that medicines supplied to the Kenyan market adhere to the requisite standards of quality, safety, and efficacy.
Paracetamol solution is used in the management of pain and fever associated with such conditions as the common cold, influenza, and headache.
For patients who are unable to tolerate solid dose formulations or lower strength preparations of paracetamol-containing products.
